GE TSCM DNDN
|
New Evidence Raises Questions About Kingsford Capital - Links To
TheS... -01/07/10 at
5:20 PM CSTby Mark
Mitchell
A blog published by the University of North
Carolina School of Journalism reported recently that Steve Cohen of
hedge fund SAC Capital managed to kill a story by Reuters reporter
Matt Goldstein. It seems that Goldstein was going to shed some
light on allegations that Cohen engaged in insider trading. Cohen
didn’t like that, and got in touch with Gol...
|
|
JPM MS BAC AIG DNDN
|
SEC OIG Investigating SEC Complicity in Naked Short Selling of
Dendre... -12/01/09 at
6:35 PM CSTby Mark
Mitchell
The Office of the Inspector General of the
Securities and Exchange Commission not long ago submitted a
semi-annual report to Congress. There are two items in the report
of interest to those of us who have argued that the SEC has turned
a blind eye towards, or even assisted, unscrupulous hedge funds
that make their fortunes destroying public companies for ...
|
|
DNDN
|
Investing in Death and Dendreon -09/23/09 at 12:49 PM CDTby Mark Mitchell
When Dendreon’s FDA application was
derailed simultaneously with a naked short selling attack that
flooded the market with tens of millions of phantom shares,
Dendreon’s supporters went berserk. They sent the government
hundreds of letters complaining about the naked short selling and
the apparent machinations of Michael Milken’s associa...
|
|
DNDN
|
Michael Milken's Prostate Cancer Foundation vs.
Dendreon -09/15/09 at
11:33 AM CDTby Mark
Mitchell
In July 2008, not long before Cell Genesys
announced that its drug was killing people, CNBC’s Jim Cramer
called Dendreon a “dog.” Cramer, of course, did not
mention that the illegal naked short selling of Dendreon was
continuing apace. Throughout that month, more than 1 million
Dendreon shares “failed to deliver” every day, a...
|
|
DNDN
|
Cell Genesys and Dendreon Inc. - If Only There Was A
Pattern -09/04/09 at
11:57 AM CDTby Mark
Mitchell
In December 2007, three U.S. Congressmen —
Mike Michaud (D-Maine), Dan Burton (R-Indiana) and Tim Ryan
(D-Ohio) — called on the House Commerce Committee to
investigate why the FDA failed to approve Dendreon’s
treatment for prostate cancer. Referring to Dr. Scher and his ally,
Dr. Hussain, the lawmakers said in a letter that
“there...
|
|
DNDN
|
PIPE Dreams at Dendreon -08/21/09 at 1:55 PM CDTby Mark Mitchell
“Black Wednesday at the FDA.” That
is how Dr. Mark Thornton, a former medical officer in the
FDA’s Office of Oncology Products, described the FDA’s
decision not to approve Dendreon’s Provenge. In an
op-ed for The Wall Street Journal, Dr. Thornton described vaccines
such as Provenge as the “Holy Grail of cancer tr...
|
|
DNDN
|
Dendreon and the Criminal Capture of the FDA
-08/13/09 at 9:30 AM
CDTby Mark Mitchell
Who in the government helped sabotage Dendreon?
Despite the lobbying by the captured doctors, despite the Wall
Street whispering, despite the singing Sendek and the media mimics
— despite all of this, it still seemed likely that the FDA
would heed the advice of its advisory panel. Instead, the FDA told
Dendreon that it would not yet approve its trea...
|
|
DNDN
|
When Dendreon Failed To Deliver -08/06/09 at 2:41 PM CDTby Mark Mitchell
On April 20, three weeks after the advisory
panel vote, and one week after Dr. Scher’s missive appeared
in The Cancer Letter, Forbes journalist Matthew Herper published a
story arguing that there was a good chance the FDA would not
approve Dendreon’s cancer treatment outright. “If the
agency wants to ask Dendreon for more data, it certa...
|
|
DNDN
|
Howard Scher's Campaign Against Dendreon
-07/31/09 at 12:16 PM
CDTby Mark Mitchell
As Dr. Scher made clear in his letter, his
concern about Dendreon was not, strictly speaking, that it
didn’t work, but that it would render irrelevant his work on
Novacea’s competing treatment, Asentar. A new phase 3 trial
to test the effectiveness of Asentar (referred to in the letter by
its medical name, DN-101) had been “designed, in...
|
|
DNDN
|
UBS Research and Other Dendreon Critics
Revisited -07/27/09 at
2:13 PM CDTby Mark
Mitchell
Adam Kidan was named as a suspect in the murder
of Gus Boulis and was questioned, but never charged. Instead, he
went to jail for his dealings with Jack Abramoff, the disgraced
Washington lobbyist. Moscatiello, the alleged Mafia bookkeeper, was
arrested and charged with the murder. When he was released on
parole, he disappeared. Lately, he has been featur...
|
|
DNDN
|
Jim Chanos, Jonathan Aschoff and More on the Dendreon
Saga -07/22/09 at 5:46
PM CDTby Mark Mitchell
When the FDA’s advisory panel voted in
favor of Provenge, most Wall Street research analysts were
predicting a bright future for Dendreon. But as naked short sellers
piled on with ever increasing gusto, hedge fund managers continued
to whisper in reporters’ ears. And two Wall Street analysts
did more than whisper – they shouted, day afte...
|
|
TSCM DNDN
|
Dendreon & Deceit: Jim Cramer, Pequot
Capital -07/19/09 at
12:02 PM CDTby Mark
Mitchell
“SELL! SELL! SELL!” shouted Jim
Cramer on March 28, 2007. The CNBC “journalist” assured
his viewers that the FDA advisory panel would vote that
Dendreon’s treatment for prostate cancer was neither safe nor
effective (notwithstanding the fact that the FDA had given the
treatment “priority review” status because Pro...
|
|